NASDAQ:APTX
Delisted
Aptinyx Inc Stock News
$0.0960
+0 (+0%)
At Close: Mar 28, 2024
Aptinyx Inc. (APTX) Reports Q2 Loss, Misses Revenue Estimates
09:25pm, Thursday, 13'th Aug 2020
Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 6.90% and -41.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Aptinyx Reports Second Quarter 2020 Financial Results and Highlights
08:05pm, Thursday, 13'th Aug 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results fo
Global Breast Implants Market (2019 to 2027) - COVID-19 Impact and Global Analysis - ResearchAndMarkets.com
12:00am, Tuesday, 11'th Aug 2020
The
The Global Pruritus Therapeutic Market will grow by USD 3.63 bn during 2020-2024
Aptinyx Inc. (APTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
04:30pm, Thursday, 06'th Aug 2020
Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO
12:00am, Thursday, 06'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
ABIOMED, Inc. (NASDAQ: ABMD)
Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) (announced a U.S. government grant for a...
Aptinyx to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
12:37pm, Tuesday, 04'th Aug 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company manage
Aptinyx to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
12:00am, Tuesday, 04'th Aug 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous sys
Aptinyx to Report Second Quarter Financial Results on Thursday, August 13, 2020
08:01pm, Thursday, 30'th Jul 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company wi
The Global Ophthalmology Devices Market will grow by $ 13.03 bn during 2020-2024
The
Global Dry Eye Syndrome Treatment Market to Surpass US$ 31 Billion by 2027, Says Coherent Market Insights (CMI)
12:00am, Wednesday, 15'th Jul 2020
The global dry eye syndrome treatment market is expected to exhibit a CAGR of 8.1% during the forecast period (2020-2027).
Aptinyx to Host PTSD-Focused R&D Day on August 5th, 2020
12:37pm, Wednesday, 08'th Jul 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it will host a
Aptinyx to Host PTSD-Focused R&D Day on August 5th, 2020
12:00am, Wednesday, 08'th Jul 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous sys
